CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01466881
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:58.984039+00:00
Published At: 2016-03-10T00:00:00+00:00
Record Updated At: 2016-03-10
Results Posted At: 2016-03-10
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Adult Nasal Type Extranodal NK/T-Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-Cell Lymphoma", "Hepatosplenic T-Cell Lymphoma", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent Adult Non-Hodgkin Lymphoma", "Recurrent Adult T-Cell Leukemia/Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-03-10"
protocolSection.identificationModule.nctId: "NCT01466881"
protocolSection.identificationModule.officialTitle: "Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2016-03-10"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.